Jeenah Moon/Getty Images News Pfizer’s ( NYSE: PFE ) COVID-19 treatment Paxlovid was found to be ineffective in lessening the symptoms of long COVID, according to a new study. Researchers at Stanford Medicine said a 15-day regimen of the drug, which is used to prevent severe COVID-19, did not lessen select symptoms of long COVID in 155 patients who had tested positive for the SARS-CoV-2 virus. Participants had been infected with the virus for at least 16 months, on average, before enrolling in the study.
All had been experiencing moderate-to-severe cases of at least two of six common COVID symptoms, including shortness of breath, brain fog, fatigue and body aches, according to Stanford Medicine . Researchers said that while Paxlovid did not appear to ease symptoms, the study showed that a 15-day course of the drug was safe. The drug is normally given for only five days.
Results of the study were published in the June 7 issue of the Journal of the American Medical Association's Internal Medicine . Stanford said the study was funded by Pfizer. More on Pfizer Pfizer: Surging Cancer Rates Will Boost Revenues Pfizer: Too Early For A Turnaround Pfizer: Too Cheap To Miss Out FDA selects JN.
1 variant for next COVID vaccine campaign Bird flu death in Mexico linked to strain not seen in humans before.
